STOCK TITAN

Artelo Biosciences (ARTL) awards director 136 stock options at $1.15

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Artelo Biosciences director Tamara A. Favorito received a grant of stock options covering 136 shares of common stock at an exercise price of $1.15 per share. The options expire on July 17, 2036 and will fully vest, subject to her continuing as a Service Provider, on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholders’ meeting following that date. After this grant, she directly holds 136 stock options.

Positive

  • None.

Negative

  • None.
Insider FAVORITO TAMARA A
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) F1 136 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 136 shares (Direct)
Footnotes (1)
  1. F1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.
Stock options granted 136 shares Stock Option (right to buy) for common stock
Exercise price $1.1500 per share Conversion or exercise price of the option
Expiration date July 17, 2036 Option expiration date
Underlying shares 136 shares Common stock underlying the option
Vesting Commencement Date July 17, 2026 Date from which vesting schedule is measured
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Vesting Commencement Date financial
""Vesting Commencement Date" shall mean July 17, 2026."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
Service Provider financial
"Subject to the Reporting Person continuing to be a Service Provider"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stock options were granted to Tamara A. Favorito at ARTL?

Tamara A. Favorito was granted stock options for 136 shares of Artelo Biosciences common stock at an exercise price of $1.15 per share. These options expire on July 17, 2036 and are reported as directly owned following the grant.

How do the new ARTL options for Tamara A. Favorito vest?

The options vest 100% if she continues as a Service Provider until the vesting date. Vesting occurs on the earlier of one year after the July 17, 2026 Vesting Commencement Date or the day before the next annual stockholders’ meeting following that date.

What is the exercise price and expiration for Tamara Favorito’s ARTL options?

The granted options have an exercise price of $1.15 per share and an expiration date of July 17, 2036. She can purchase up to 136 shares of Artelo Biosciences common stock at that price once the options are vested.

How many ARTL options does Tamara Favorito hold after this grant?

Following this reported transaction, Tamara A. Favorito directly holds 136 stock options for Artelo Biosciences common stock. Each option relates to one underlying share, giving rights to purchase 136 shares in total once vested and exercised.

Is Tamara Favorito’s ARTL option vesting dependent on continued service?

Yes. The footnote states vesting is conditioned on her continuing to be a Service Provider under the company’s plan through the applicable vesting date. Without continued service, the 100% cliff vesting described would not be satisfied.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
FAVORITO TAMARA A

(Last)(First)(Middle)
C/O ARTELO BIOSCIENCES, INC.
505 LOMAS SANTA FE, SUITE 160

(Street)
SOLANA BEACH CALIFORNIA 92075

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.1507/17/2026A136 (1)07/17/2036Common Stock136$0.00136D
Explanation of Responses:
1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean July 17, 2026.
/s/ Gregory D. Gorgas, as Attorney-in-Fact07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)